

Table of Contents

About the Authors	iii
Preface	xvii
Introduction	xxi

PART 1: IS ADHD A REAL DISORDER?

Chapter 1: Validity of the Diagnosis and Dimensions of Attention Deficit Hyperactivity Disorder

Introduction	1-2
Dimensions of ADHD Symptoms: Internal Validity of	
DSM-IV Model	1-3
Discriminant Validity of the Two-Dimensional Structure of ADHD	1-3
Differential Association of the Two Dimensions of Symptoms	
With Concurrent Mental Disorders	1-3
Differential Association of the Two Dimensions of Symptoms	
With Types of Impairment	1-4
Developmental Course of the Two Dimensions of	
ADHD Behaviors	1-5
Correspondence of DSM-IV ADHD to DSM-III-R ADHD	1-5
Correspondence of DSM-IV ADHD to ICD-10 Hyperkinesis	1-7
Validity of the Diagnosis of ADHD	1-7
Face Validity	1-8
Predictive Validity of ADHD in Childhood	1-8
Concurrent Validity of ADHD	1-8
Validity of DSM-IV Criteria for Age of Onset and	
Cross-Situational Impairment	1-10
Discriminant Validity of the Subtypes of DSM-IV ADHD	1-11
ADHD and Comorbid Mental Disorders	1-13
ADHD in Adulthood	1-14
Assessment of ADHD	1-14
Is ADHD Better Conceptualized in Diagnostic or Dimensional	
Terms?	1-14
Recommendations for Clinical Practice, Policy, and Future	
Research	1-15
Implications for Clinical Practice	1-15
Implications for Public Policy	1-16
Areas to Target in Future Research	1-16

Chapter 2: The Diagnostic Classification, Epidemiology, and Cross-Cultural Validity of ADHD

Introduction	2-1
Changes in the Nosology and Effects on Rates	2-2
Earlier Diagnostic Definitions	2-2
Current Diagnostic Taxonomies	2-2
Unresolved Classification Issues	2-3
Prevalence of the Disorder	2-3
Cross-Cultural Validity of the Construct	2-6
Presence of a Syndrome of Hyperkinesia/ADHD in Different Settings	2-8
Analysis of Epidemiological Data	2-9
Risk Factors and Comorbidities	2-9
Other Outcomes	2-11
Summary	2-12

Chapter 3: Is ADHD a Valid Disorder?

Overview	3-1
The ADHD Diagnosis	3-2
Increasingly Frequent Diagnosis	3-2
Shortcomings of Diagnostic Criteria	3-3
An Area of Consensus	3-3
Major Diagnostic Problems	3-4
ADHD Behaviors Not Clearly Distinguishable From Normal Temperament Variations	3-5
Absence of Clear Evidence That ADHD Symptoms Are Related to Brain Malfunction	3-7
Neglect of the Role of the Environment and Interactions With It as Factors in Etiology	3-8
Diagnostic Questionnaires Now in Use Are Highly Subjective and Impressionistic	3-9
Most Important Predisposing Factors May Be Low Adaptability and Cognitive Problems	3-10
Lack of Evolutionary Perspective	3-12
Small Practical Usefulness and Possible Harm From Label	3-12
Widespread Misapplication of the Present ADHD Label	3-13
Nonspecific Effects of Methylphenidate and Other Stimulants	3-14
Conclusion	3-14

Chapter 4: ADHD—Long-Term Course, Adult Outcome, and Comorbid Disorders

Introduction	4-1
Limitations of Methodology	4-2
Lack of Consensus on Diagnostic Criteria	4-2
Use of Different Assessment Instruments	4-2
Unreliability of Measurement Over Time	4-3
Developmental Issues	4-3
Shifting Information Sources	4-4
Attrition	4-4
Outcome at Adolescence	4-5
Persistence of ADHD Symptoms	4-5
Occurrence of Comorbid Disorders	4-6
Outcome at Adulthood	4-7
Persistence of ADHD Symptoms	4-7
Risk for Antisocial or Criminal Behavior	4-8
Risk of Substance Abuse	4-9
Risk of Mood Disorders	4-10
Conclusion	4-10

Chapter 5: Is ADHD an Impairing Condition in Childhood and Adolescence?

Introduction	5-2
Methodological and Conceptual Issues	5-3
Current Definitions of ADHD May Lead to Circular Reasoning Regarding Impairment	5-3
Types of Samples and Kinds of Measures Used to Appraise Impairment Crucial to Unbiased Definitions	5-3
Comorbidities, Rather Than ADHD Per Se, May Explain Impairment	5-4
Which Subtypes of ADHD Show Impairment?	5-5
Does Impairment Change Across the Developmental Span From Preschool to Adolescence?	5-5
Summary	5-5
ADHD-Related Impairment: Evidence	5-6
Academic Achievement and School Functioning	5-6
Academic Achievement	5-6
School-Related Impairment: Special Education, Suspension, Expulsion	5-7
Summary	5-7

Family Relationships and Home Life	5-8
Impaired Family Relationship Patterns	5-8
Escalating Pattern of Discordant	
Interchanges	5-8
Impact of Comorbid Aggression	5-9
Summary	5-9
Peer Relationships	5-10
Peer Rejection	5-10
Impact of Comorbid Aggression	5-10
Effect of ADHD Subtype on Likelihood of	
Rejection	5-11
ADHD Children's Social Competence	5-11
Summary	5-12
Self-Esteem and Self-Perception	5-12
Lower Self-Esteem	5-12
Overconfidence	5-12
Summary	5-12
Accidental Injury	5-13
Personal and Familial Variables	5-13
Developmental Factors	5-13
Summary	5-14
Overall Adaptive Functioning	5-14
Conclusions	5-14
Summary of Findings	5-14
Practical Implications	5-16

Chapter 6: The Impact of Attention Deficit Hyperactivity Disorder on Social and Vocational Functioning in Adults

Introduction	6-2
Identification and Study of ADHD in Adults	6-2
Challenges to Reliability of Diagnosis	6-3
Lack of Consensus on Diagnostic Criteria	6-3
Manifestation of ADHD in Adults	6-3
Reliability of Childhood History	6-4
Differentiation of ADHD From Other	
Disorders	6-4
Prevalence of Adult ADHD	6-4
Summary	6-5
Evaluating Evidence of the Impact of ADHD on Adult	
Functioning	6-6

Educational and Vocational Functioning in Adults With ADHD	6-7
Montreal Longitudinal Study	6-7
New York Longitudinal Study	6-8
Other Findings	6-8
Lifelong Impact of Childhood Difficulties	6-9
Employment Discrimination Challenges	6-9
Summary	6-10
Social Functioning in Adults With ADHD	6-10
Impairments in Psychological Functioning	6-11
Social Skills Deficits	6-13
Family Functioning	6-13
Marital Ties	6-13
Parenting	6-14
Conclusions	6-15
Recommendations for Clinical Practice and Future Research	6-16

PART 2: WHAT CAUSES ADHD?

Chapter 7: Biological Bases of ADHD—Neuroanatomy, Genetics, and Pathophysiology

Introduction	7-1
DSM-IV/ICD-10 Overlap	7-2
Dopamine Theory of ADHD	7-4
Research on Neuroanatomical Abnormalities	7-4
Differences in Neuroanatomic Structures in Children	
With ADHD	7-5
Basal Ganglia and Cerebellum	7-5
Frontal Regions	7-6
Areas of Difference Among the Findings	7-6
Overall Consistency of Findings	7-7
Research on Functional Brain Imaging and ADHD	7-7
Genetic Investigations	7-9
Twin Studies	7-9
Genes Associated With ADHD/HKD	7-9
Populations and Family Studies of Candidate Genes	7-10
DRD4 Gene	7-11
DAT1 Gene	7-11
Study Replications	7-12
Investigations of Nongenetic Etiologies	7-12

Neurobiological Bases for Pharmacological Treatment	7-13
Methylphenidate as a Dopamine Blocker	7-13
Debate Regarding Net Effect of Dopamine Blockade	7-14
Alternative Site-of-Action Hypotheses	7-14
Summary	7-15

Chapter 8: Cognitive Correlates of ADHD

Introduction	8-2
Conceptual and Methodological Challenges	8-3
Diverse and Shifting Definitions of ADHD	8-3
Effect of Co-Occurring Disorders, Age, and Gender	8-3
State of the Science	8-4
Impact on Current Study	8-4
General Intellectual Function	8-4
Academic Achievement	8-6
Low Productivity	8-6
Underachievement	8-6
Academic Outcomes	8-7
Neuropsychological Function	8-8
Impairments in Executive Functioning	8-8
Other Neuropsychological Impairments	8-9
Cognitive Functions Not Directly Affected by ADHD	8-10
Summary	8-10
Impact of Comorbidity on Neuropsychological Profile	8-10
Reading Disorder	8-10
Anxiety Disorder	8-11
Conduct Disorder	8-11
Specificity of Cognitive Correlates to Neuropsychological Functioning	8-12
Information Processing	8-13
Impairments in Sustained Attention	8-13
Response Inhibition Deficits	8-14
Spatial Allocation of Attention	8-15
Implications for Neural Substrate and Pathophysiology of ADHD	8-15
Clinical Implications	8-16
Diagnosis	8-16
Assessment and Treatment	8-17
Implications for Future Research	8-18

PART 3: ARE ADHD TREATMENTS SAFE AND EFFECTIVE?

Chapter 9: Stimulant Medication Treatment of Children With Attention Deficit Hyperactivity Disorder

Introduction	9-2
Pharmacology	9-3
Absorption and Metabolism	9-4
Toxicology	9-6
Stimulant Adverse Events	9-6
Are There Long-Term Risks of Stimulant Use?	9-6
Short-Term Efficacy Shown in Randomized Controlled Trials of Stimulants	9-7
Benefits of Stimulant Medications	9-9
Amelioration of Disruptive Behaviors	9-9
Improvement of Cognitive Functioning	9-9
Placebo vs. Medication Response	9-9
Efficacy of Long-Duration Stimulant Preparations	9-12
Limitations of Short-Term Stimulant Trials	9-13
Long-Term Randomized Controlled Trials of Stimulant Medications	9-14
The MTA Study	9-14
MTA Study Design	9-14
Study Outcome	9-18
MTA Study's Answers to Treatment Questions	9-18
Other Long-Term Studies	9-19
Issues for Practitioners	9-19
Do the Research Findings Inform Practice?	9-19
Limitations of Available Stimulants	9-20
Response/Dosing Issues	9-20
Side Effects	9-21
Recommendations	9-21

Chapter 10: Public Health and Toxicological Issues Concerning Stimulant Treatment for ADHD

Introduction	10-2
Prevalence	10-2
Toxicology	10-3
Methylphenidate	10-3

Amphetamines	10-4
Pemoline (Cylert)	10-5
Efficacy of Stimulant Treatment	10-5
Short-Term Efficacy	10-5
Long-Term Effectiveness	10-6
Safety	10-7
Short-Term Safety	10-7
Methylphenidate and Amphetamines	10-7
Pemoline (Cylert)	10-7
Long-Term Safety	10-8
Limits of Adverse Drug-Reporting Systems	10-8
Need for Large-Scale Cohort and Drug Surveillance Studies	10-9
Phenobarbital as Analogy	10-10
Future Research Needs	10-11
Toxicology	10-11
Efficacy/Effectiveness	10-11
Safety	10-12
An Opportunity and a Responsibility	10-12

Chapter 11: Nonstimulant Treatments for ADHD

Introduction	11-1
Evolving Nosology of ADHD	11-2
Drawbacks of Using Stimulants to Treat ADHD	11-2
Alternative Treatments for ADHD: Tricyclic Antidepressants	11-4
Advantages of TCAs	11-4
Favorable Results With Desipramine	11-4
DMI in Treating Children	11-4
DMI in Treating Adults	11-5
Efficacy of Nortriptyline	11-5
Comparison of TCAs to Stimulants	11-5
Safety of TCAs	11-6
Non-TCA Antidepressants	11-6
Bupropion	11-6
MAOIs and SSRIs	11-6
Tomoxetine	11-7
Alpha-2 Noradrenergic Agonists	11-7
Other Drugs	11-7
New Directions: Cholinergic Drugs	11-8

Summary and Discussion	11-9
Viability of Nonstimulant Treatments	11-9
Need for Further Research	11-10

Chapter 12: Psychosocial Interventions for ADHD

Introduction	12-2
Limitations of Pharmacological Interventions	12-3
Little Effect on Interpersonal Relationships or Family	
Functioning	12-3
Individual Differences in Response	12-3
Long-Term Prognosis Discouraging	12-4
Psychosocial Interventions	12-4
Cognitive-Behavioral Treatment	12-5
Clinical Behavior Therapy	12-6
Improved Behavior	12-8
Impact on School Functioning	12-9
Effect of Concurrent Medication	
Therapy	12-10
Contingency Management	12-10
Use of Negative Consequences	12-11
Treatment Effects	12-11
Intensive Treatments	12-12
The Children's Summer Treatment Program	12-12
Treatment Response	12-13
Need for Comprehensive Long-Term	
Intervention	12-14
Shortcomings of Behavioral Interventions	12-14
Combined Pharmacological and Behavioral Interventions	12-15
Advantages of Combining Behavioral and Pharmacological	
Treatments	12-15
Long-Term Impact	12-16
Research Findings Show Positive Results	12-16
Long-Term Efficacy	12-18
Summary and Future Directions	12-18
Efficacy of Behavioral Treatment Is Clear	12-18
Open Questions	12-19
Does Child's Age Affect Treatment Choice?	12-19
How Should Comorbidities Affect Treatment	
Choice?	12-21
How Do Family Factors Affect Treatment Choice?	12-21

Can Medication Dosage or Parent Training Mitigate Treatment Intensity?	12-21
What Is Optimum Treatment Sequence?	12-22
How Long Must Treatment Continue?	12-22
Cost-Effectiveness	12-23
Exportability of Programs to Real-World Settings	12-24
Long-Term Effectiveness	12-24

Chapter 13: Treatment Alternatives for Attention Deficit Hyperactivity Disorder

Introduction	13-2
Elimination Diets (Few-Foods Diets/Oligoantigenic)	13-2
Recent Research Documents Efficacy	13-2
Probable Responders to Elimination Diets	13-3
Sugar Elimination Alone Unlikely to Work	13-4
Possible Risks	13-7
Immune Therapy	13-7
Nutritional Supplements	13-7
Amino Acid Supplementation	13-7
Essential Fatty Acid Supplementation	13-8
Possible L-Carnitine Effect	13-9
Glyconutritional Supplements	13-9
Dimethylaminoethanol	13-9
Vitamin Supplementation	13-10
Mineral Supplements	13-11
Iron Supplementation	13-11
Zinc Supplementation	13-11
Magnesium Supplementation	13-12
Herbal and Homeopathic Treatments	13-12
Acupuncture	13-13
EEG Biofeedback	13-13
EMG Biofeedback, Relaxation Training, and Hypnosis	13-14
Meditation	13-15
Mirror Feedback	13-15
Perceptual Stimulation/Training	13-15
Massage	13-15
Vestibular Stimulation	13-16
Channel-Specific Perceptual Training	13-17
Antifungal Treatment	13-17
Thyroid Treatment	13-17
Deleading	13-18

Recommendations for Clinical Practice	13-18
Weighing Alternatives	13-18
Category 1: Unproven	13-18
Category 2: Ineffective/Unsafe	13-19
Category 3: Indicated Only for Selected Etiologies	13-19
Category 4: Proven Efficacy	13-19
Category 5: Worth Trying Despite Limited Evidence of Efficacy	13-20
Approach to Selecting Treatment	13-20
Recommendations for Future Research	13-20

Chapter 14: Behavioral and Medication Treatments for ADHD— Comparisons and Combinations

Background	14-2
Short-Term Treatment Studies	14-4
Medication vs. Behavior Therapy vs. Combined Treatment	14-4
Medication/Psychosocial Treatment 2 x 3 Study	14-4
Small-Sample Studies	14-4
Cognitive Treatment Plus Medication vs. Medication Alone	14-4
Behavior Treatment With and Without Medication	14-5
Dose-Reduction Study	14-5
Medication With and Without Auditory Feedback or Contingency Management	14-6
Durability of Treatment	14-6
Studies Favoring Combined Treatment Over Medication Alone in the Minority	14-7
Long-Term Treatment Studies	14-8
The MTA Study	14-9
Intensive Psychosocial/Behavioral Treatment vs. Medication Management	14-9
Combined Treatment vs. Unimodal Treatments	14-9
MTA-Delivered Treatments vs. Community Standard Care	14-10
Summary of MTA Findings	14-10
Research Limitations	14-10
Small Samples	14-10
Short Duration of Most Studies	14-11
Insufficiently Intensive Psychosocial Treatment	14-11
Treatments Not Adjusted to Subject-Specific Needs	14-11

Summary and Conclusion	14-12
Future Research Needs	14-12

Chapter 15: Matching Patients to Treatments

Introduction	15-1
ADHD and Disruptive Behaviors	15-2
Response to MPH Treatment	15-2
Stimulant vs. Psychosocial Treatment	15-3
ADHD and Anxiety Disorders	15-4
Response to Medication	15-4
Stimulant vs. Psychosocial Treatment	15-5
ADHD and Comorbidity Patterns	15-7
ADHD and Mood Disorders	15-7
ADHD and Mental Retardation	15-8
ADHD Subtypes	15-9
Recommendations for Clinical Practice	15-9
Children Who Clearly Benefit From Stimulant Treatment	15-10
Treatment of Children With Internalizing Problems	15-10
When Psychosocial Treatment Is Indicated	15-10
Gray Areas	15-11
Recommendations for Future Research	15-11

PART 4: DOES STIMULANT USE FOR ADHD LEAD TO SUBSTANCE ABUSE?

Chapter 16: Alcohol, Stimulants, Nicotine, and Other Drugs in ADHD

Introduction	16-1
Rationale for Hypothesis That Individuals With ADHD Are Likely to Abuse Drugs	16-2
Retrospective Surveys of ADHD in Substance Use Disorders (Adults and Adolescents)	16-3
ADHD and Alcohol-Related Disorders	16-3
ADHD and Cocaine Use	16-5
ADHD and Use of Opiates	16-6
ADHD and Mixed Substance Use Disorders	16-6
Retrospective Reports of Drug Use and Abuse in Adults With ADHD	16-7
Retrospective Report in Adolescents in the General Population	16-8
Current ADHD and Patterns of SUD	16-8
Longitudinal Studies of Children With ADHD	16-9

Clinical Studies	16-9
Community Studies	16-11
Public Health and Clinical Implications	16-12
Problems in Drawing Inferences From Multiple Studies	16-13
The Conduct Disorder Link	16-14
Conclusions	16-15

Chapter 17: Medicated vs. Unmedicated ADHD Children—Adult Involvement With Legal and Illegal Drugs

Introduction	17-2
Implicit Theories About Medication and Drug Abuse	17-3
Theories That Medication Causes or Predisposes to Drug Abuse	17-3
Pharmacological Predisposition	17-3
Psychological Predisposition	17-3
Theories That Medication Prevents or Protects Against Drug Abuse	17-3
Pharmacological Protection	17-4
Psychological Protection	17-4
Findings From Early Investigations	17-4
Recent California Study	17-5
New Iowa Study	17-5
Who Was Chosen to Receive Medication, and Why	17-5
Follow-up Review of Patients' Attitudes Toward and Experience With ADHD Medication	17-6
Central Questions About Childhood Medication and Drug Abuse	17-7
Adult Attitudes About Medication Prescribed in Childhood	17-7
Relationships Between Childhood Medication Status and Adult Attitudes About Drugs	17-8
Relationships Between Childhood Medication Status and Later Involvement With Drugs	17-8
Relationships Between Childhood Medication Status and Adult Psychiatric Diagnoses	17-11
Implications of Newer Studies	17-11
Future Directions	17-13

Chapter 18: Stimulant Treatment as a Risk Factor for Nicotine Use and Substance Abuse

Introduction	18-2
Perspectives on ADHD as a Risk Factor for Tobacco Smoking and Substance Use	18-3

Hypotheses Pertaining to Higher Rates of Smoking and Substance Use by ADHD Individuals	18-3
Self-Medication Hypothesis	18-3
Stimulant Treatment Sensitization Hypothesis	18-4
Other Risk Factors for Substance Use	18-5
Tobacco as the Gateway to Substance Use	18-5
Problem Behavior as a Risk Factor for Substance Use	18-6
Research Objectives and Methods	18-6
Hypotheses Explored	18-6
Study Participants	18-7
Development of Research Diagnostic Proxies for ADHD	18-7
DSM-IV Criteria of Onset of Symptoms	18-8
Criteria for Severity of ADHD	18-8
DSM-IV ADHD Classification Compared With Original Classification of Subjects	18-9
Procedures for Collecting Tobacco and Substance Use Data	18-9
Variables in the Statistical Analyses	18-10
Dependent Variables	18-10
Independent Variables	18-11
Statistical Analysis	18-12
Study Results	18-12
Survival Analyses	18-12
Survival Analysis of Delay in Onset of Regular Smoking by Severity of ADHD	18-12
Survival Analysis of Delay in Onset of Regular Smoking by Use of CNS Stimulant Treatment in Childhood	18-13
Relationship of Severity of ADHD and Childhood Stimulant Treatment to Adult Smoking	18-15
Multivariate Prediction of Adult Daily Smoking and DSM-III-R Psychoactive Substance Use Disorders	18-15
Support for the Self-Medicating Hypothesis	18-17
Support for the Sensitization Hypothesis	18-18
Partial Support for Tobacco Gateway Hypothesis	18-19
Childhood Problem Behavior Not Supported as a Factor in PSUD	18-19
Conclusion	18-20

Chapter 19: Attention Deficit Hyperactivity Disorder and Substance Use Disorders—The Nature of the Relationship, Subtypes at Risk, and Treatment Issues

Introduction	19-1
------------------------	------

Overlap Between ADHD and SUD	19-2
ADHD as a Risk Factor for SUD	19-3
Longitudinal Studies: ADHD	19-3
ADHD Treatment and SUD	19-3
Longitudinal Studies of SUD	19-5
SUD Pathways Associated With ADHD	19-5
Familial Relationships Between ADHD and SUD	19-6
Implications of Current Research	19-7
Increased Risk of SUD for ADHD Youth	19-8
Parental SUD a Risk Factor for Juvenile ADHD/Conduct Disorder	19-8
Self-Medication a Likely Factor	19-8
Impact of Psychosocial Risk Factors	19-9
Diagnosis and Treatment Guidelines	19-10
Evaluation	19-10
Stabilization of the Addiction	19-10
Psychotherapeutic Interventions	19-11
Pharmacotherapy	19-11
Summary	19-12

Chapter 20: Diversion, Trafficking, and Abuse of Methylphenidate

Introduction	20-1
Abuse Liability Studies	20-2
Amphetamine- and Cocaine-Like Effects	20-2
Dose-Reinforcing Effects	20-2
Disruptive and Stimulus Effects	20-5
Summary	20-6
MPH Manufacture, Distribution, and Use	20-7
Increased Production and Sale	20-7
Disparities in Usage	20-8
Diversion and Trafficking	20-9
Issues Related to MPH Medication for ADHD	20-12
Growing Problem of Abuse by Schoolchildren	20-12
Increased Abuse Among Adolescents	20-12
Diversion of Children's Prescribed Medication	20-14
Three-State Diversion Survey Findings	20-15
Why and How Survey Was Conducted	20-15
MPH Diversion Not Rare	20-15
Factors Contributing to Diversion of MPH Intended for ADHD Treatment	20-16
Conclusion	20-17

Chapter 21: Availability of Stimulant Medications—Nature and Extent of Abuse and Associated Harm

Introduction	21-1
Monitoring the Future	21-4
Design and Methodology	21-4
Sampling Procedures	21-5
Questions Pertaining to the Medical and Nonmedical Use of Amphetamines	21-5
The Drug Abuse Warning Network	21-6
Design and Methodology	21-6
DAWN Sample	21-7
Community Epidemiology Work Group	21-8
What the Ongoing Studies Reveal About Drug Abuse	21-8
MTF Results	21-8
DAWN Results	21-10
CEWG Results	21-13
Discussion	21-13

Chapter 22: Treatment Services for Children With ADHD—A National Perspective

Introduction	22-2
Prevalence of Attentional Problems and Available Services	22-3
Review of Treatment Services	22-4
Trends in Prescription Practices	22-4
Increasing Levels of Prescribing	22-4
Prevalence of Medication Treatments	22-5
Rates of Specialty Mental Health and School Services Received	22-5
Variations in Treatments or Use of Services	22-6
Gender Variations	22-6
Racial Variations	22-6
Geographical Variations	22-6
Barriers to Care	22-6
Conclusions From the Review	22-7
The National Ambulatory Medical Care Survey	22-8
Survey Methods	22-8
Data Set	22-8
Data Assessment	22-8
Increased Identification of ADHD	22-9
Trends in Types of Treatments and Services	22-9
Medication Management	22-10

Diagnostic Services	22-10
Counseling Services	22-10
Follow-up Services	22-11
Types of Services by Provider Type	22-11
Medication Management	22-11
Diagnostic Services	22-11
Mental Health Counseling	22-11
Other Counseling	22-11
Psychotherapy	22-11
Specific Follow-up	22-12
The Child Behavior Study	22-12
Survey Methods	22-12
Receipt of Specialty Mental Health Services and Stimulant Treatments	22-13
Service Mix	22-13
Identified Barriers to Care	22-13
Conclusions and Recommendations	22-13
Service Patterns and Continuing Problems	22-13
Continuing Barriers to Care	22-15
Recommendations for Clinical Practice and Policy	22-15
Recommendations for Future Research	22-16

**PART 5: EXISTING PRACTICES AND POLICIES REGARDING
ASSESSMENT AND TREATMENT OF ADHD**

Chapter 23: Current Assessment and Treatment Practices in ADHD	
Introduction	23-1
History of ADHD	23-2
Evolving Medical Interest	23-2
Educational Interest	23-2
Treatment Diversity and Controversy	23-3
Role of Primary Care Physicians vs. Mental Health Clinicians	23-3
Diagnosis	23-4
Importance of Multidisciplinary Communication	23-4
Spectrum of Behavioral Symptoms	23-4
School and Primary Care Process in Terms of Diagnosis and Treatment	23-5
Presence and Diagnosis of Comorbidity With Other Cognitive and Behavioral Disorders	23-6

Treatment	23-7
Use of Stimulants and Other Psychotropic Medications	23-7
School System Concerns Regarding Treatment	23-7
School's Role in Use of Nondrug Therapies	23-8
Physician Follow-up and Assessment of Treatment	23-8
Need for Systematic Methods to Provide Comprehensive Services	23-9
Summary	23-10

Chapter 24: Impact of ADHD on School Systems

Introduction	24-1
Children With ADHD in Special Education	24-3
Learning Disabilities	24-3
Emotional Disturbance	24-4
Other Health Impaired	24-5
Estimates of ADHD Eligibility in Special Education	24-7
Cost Estimates	24-8
Impact of ADHD on Schools	24-9
Impact on Segregated Classroom	24-10
Impact on Inclusive or Mainstream Classrooms	24-12
Conclusions and Recommendations	24-14
Research	24-15
Training	24-15
School Practice and Policy	24-16

Chapter 25: The Impact of Attention Deficit Hyperactivity Disorder on the Juvenile Justice System

Introduction	25-1
Trends in Juvenile Offending	25-1
Growth in Number of Detained Juveniles	25-1
Prevalence of Mental Health Disorders, ADHD, and Conduct Disorders Among Youth in the Juvenile Justice System	25-2
Relationship of ADHD and CD to Antisocial and Violent Behavior	25-3
Juvenile Justice System Response	25-3
Research Needs	25-4

Chapter 26: Educational Policy—Educating Children With Attention Deficit Hyperactivity Disorder

Introduction	26-1
Federal Policy History	26-2
Background	26-2

Joint Federal Policy Memorandum	26-2
IDEA Eligibility	26-2
Rehabilitation Act Section 504 Eligibility	26-3
Federal Support for ADHD Research and Technical Assistance	26-3
U.S. Department of Education Activities Since 1991	26-4
Revised IDEA Regulations	26-5
State Education Agency Policies	26-6
Background	26-6
Adoption of Written Policies	26-6
ADHD as Part of a Disability Category	26-7
Policies Specific to Identification and Assessment of ADHD	26-7
Policies Regarding Medication of Students With ADHD	26-8
Prevalence of ADHD in States	26-8
Technical Assistance Needs of State and Local Educators	26-8
ADHD as an “Other Health Impairment”	26-9
Discussion and Implications	26-10

Chapter 27: Use of Services and Costs for Youth With ADHD and Related Conditions

Introduction	27-2
Prevalence of ADHD in Primary Care Settings	27-2
ADHD Increasingly Diagnosed	27-2
Demographic Factors	27-3
Frequency of Comorbidity	27-3
Summary	27-4
Use of Services	27-4
The Child Behavior Study	27-5
Setting	27-5
Sample	27-5
Procedures	27-6
Measures	27-6
Clinician-Reported Items (Clinician Identification)	27-6
Parent- or Guardian-Reported Items (Services Use)	27-6
Analysis	27-6
Results	27-7
Increased Use of Many Types of Health Services	27-7
Predictors of Receipt of Specific Treatment Services	27-7

Costs of Care—ADHD Cost of Services in Medicaid Study for
 Southwestern Pennsylvania 27-8
 Setting 27-9
 Sample 27-9
 Procedures 27-9
 Measures 27-10
 Analysis 27-10
Need for Cost-Benefit Analysis 27-11
Conclusion 27-12

Afterword: ADHD, Past, Present, and Future A-1

Appendix A: National Institutes of Health Consensus Statement App. A-1
Appendix B: Bibliography App. B-1
Index I-1